Foscarnet for Treatment of Cytomegalovirus Infections in Bone Marrow Transplant Recipients

References

• Neiman P E, Reeves W, Ray G, Flournoy N, Lerner K G, Sale G E, Thomas E D. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow graft. J Infect Dis 1977; 136: 754–767
   PubMed Web of Science ®Google Scholar
• Winston D J, Gale R P, Meyer D V, Young L S, The UCLA Bone Marrow Transplantation Group. Infectious complications of human bone marrow transplantation. Medicine 1979; 58: 1–31
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142: 816–824
   PubMed Web of Science ®Google Scholar
• Paulin T, Ringdén O, Lönnqvist B, Wahren B, Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. Scand J Infect Dis 1986; 18: 199–209
   PubMed Web of Science ®Google Scholar
• Meyers J D, Spencer H C, Jr, Watts J C, Gregg M B, Stewart J A, Troupin R H, Thomas E D. Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 1975; 82: 181–188
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience. Rev Infect Dis 1982; 4: 1119–1131
   PubMedGoogle Scholar
• Paulin T, Ringdén O, Lönnqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1985; 39: 377–384
   PubMed Web of Science ®Google Scholar
• Ch'ien L T, Cannon N J, Whitley R J, Diethelm A G, Dismukes W E, Scott C W, Buchanan R A, Alford C A, Jr. Effect of adenine arabinoside on cytomegalovirus infection. J Infect Dis 1974; 130: 32–39
   PubMed Web of Science ®Google Scholar
• Meyers J D, McGuffin R W, Neiman P E, Singer J W, Thomas E D. Toxicity and efficacy of human leukocyte interferon for the treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 1980; 141: 555–562
   PubMed Web of Science ®Google Scholar
• Meyers J D, McGuffin R W, Bryson Y J, Cantell K, Thomas E D. Treatment of cytomegalovirus pneumonia after marrow transplantation with combined vidarabine and human leukocyte interferon. J Infect Dis 1982; 146: 80–84
   PubMed Web of Science ®Google Scholar
• Wade J C, Hintz M, McGuffin R W, Springmeyer S C, Connor J D, Meyers J D. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 1982; 73: 249–256
   PubMed Web of Science ®Google Scholar
• Wade J C, McGuffin R W, Springmeyer S C, Newton B, Singer J W, Meyers J D. Treatment of cytomegalovirus pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis 1983; 148: 557–562
   PubMed Web of Science ®Google Scholar
• Meyers J D. Cytomegalovirus infection following marrow transplantation: Risk, treatment and prevention. Birth Defects 1984; 20: 101–117
   PubMedGoogle Scholar
• Meyers J D, Leszcynski J, Zaia J A, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–446
   PubMed Web of Science ®Google Scholar
• Reed E C, Bowden R A, Dandliker P, et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 1987; 156: 641–645
   PubMed Web of Science ®Google Scholar
• Shepp D H, Dandliker P S, de Miranda P, Burnette T C, Cederberg D M, Kirk L E, Meyers J D. Activity of 9-[2-hydroxymethyl) ethoxymethyl]-guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368–373
   PubMed Web of Science ®Google Scholar
• Emanuel D, Cunningham I, Jules-Elysee K, Brochstein J A, Kernan N, Laver J, Stover D, White D, Fels A, Polsky B, Castro-Malaspina H, Peppard J, Bartus P, Hammerling U, O'Reilly R. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–782
   PubMed Web of Science ®Google Scholar
• Reed E C, Bowden R A, Dandliker P S, Lilleby K E, Meyers J D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–788
   PubMed Web of Science ®Google Scholar
• Schmidt G M, Kovacs A, Zaia J A. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905–907
   PubMed Web of Science ®Google Scholar
• Verdonck L F, de Gast G C, Dekker A W, et al. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989; 4: 187–189
   PubMed Web of Science ®Google Scholar
• Aulitzky W E, Tilg H, Niederwieser D, Hackl M, Meister B, Huber C. Ganciclovir and hyperimmunglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. J Infect Dis 1988; 158: 488–489
   PubMed Web of Science ®Google Scholar
• Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, Cordonnier C, Debusscher L, De Laurenzi A, Kolb H J, Messina C, Newland A C, Niederwieser D, Prentice H G, Richard C, Ruutu T, Verdonck L. Cytomegalovirus interstitial pneumonitis; treatment with ganciclovir and intravenous immune globulin. EBMT experience, Submitted
   Google Scholar
• Eriksson B, Öberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus of cellular origin. Acta Biochim Biophys Hung 1982; 696: 115–123
   Google Scholar
• Öberg B. Antiviral effects of phosphonoformate. Pharmacol Ther 1989; 40: 213–285
   PubMed Web of Science ®Google Scholar
• Sandström E G, Kaplan J C, Byington R E, Hirsch M S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1985; 1: 1480–1482
   PubMed Web of Science ®Google Scholar
• Dohin E, Katlama C, Cochereau I, Ingrand D, Le Hoang P, et al. Intermittent and ambulatory treatment of CMV retinitis with foscarnet in AIDS. Abstract Th. B. 434, 6th International Conference on AIDS, San Francisco, June, 20–241990
   Google Scholar
• Mills J, Jacobson M A, O'Donnell J J, Cederberg D, Holland G N. Treatment of cytomegalovirus retinitis in patients with AIDS. Rev Infect Dis 1988; 10(Suppl 3)522–531
   Google Scholar
• Ringdén O, Bäckman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P, Gahrton G. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41–51
   PubMed Web of Science ®Google Scholar
• Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B. Prevention of graft-versus-host disease with T cell depletion or cyclosporin combined with methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221–226
   PubMed Web of Science ®Google Scholar
• Ringdén O, Lönnqvist B, Paulin T, Ljungman P, Wahren B, Lernestedt J-O. A pilot trial using foscarnet for cytomegalovirus infections in marrow transplant recipients. Progress in bone marrow transplantation, R P Gale, R Champlin. Alan R. Liss, New York 1987; 589–593
   Google Scholar
• Sundqvist V A, Wahren B. An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods 1981; 2: 301–312
   PubMed Web of Science ®Google Scholar
• Ringdén O, Lönnqvist B, Paulin T, Ahlmén G, Klintmalm G, Wahren B, Lernestedt J-O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373–387
   PubMed Web of Science ®Google Scholar
• Gaub J, Pedersen C, Poulsen A-G, Mathiesen L R, Ulrich K, et al. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1987; 1: 27–33
   PubMed Web of Science ®Google Scholar
• Chrisp P, Clissold S P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104–129
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488
   PubMed Web of Science ®Google Scholar
• Paulin T, Ringdén O, Ljungman P, Nilsson B. Symptomatic cytomegalovirus infection after bone marrow transplantation. Clin Transplant 1989; 3: 279–285
   Web of Science ®Google Scholar
• Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113–119
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Kopecky K J, Jocom J, Fisher L, Buckner C D, Meyers J D, Counts G W, Bowden R A, Petersen F B, Witherspoon R P, Budinger M D, Schwartz R S, Appelbaum F R, Clift R A, Hansen J A, Sanders J E, Thomas E D, Storb R. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705–712
   PubMed Web of Science ®Google Scholar
• Grundy J E, Shanley J D, Griffiths P D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?. Lancet 1987; 2: 996–999
   PubMed Web of Science ®Google Scholar
• Manischewitz J F, Quinnan G V, Jr, Lane H C, Wittek A E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34: 373–375
   PubMed Web of Science ®Google Scholar
• Freitas V R, Fraser-Smith E B, Matthews T R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 1989; 12: 205–212
   PubMed Web of Science ®Google Scholar